9月23日，中巨芯涨1.04%，成交额5.95亿元。两融数据显示，当日中巨芯获融资买入额7054.29万元， 融资偿还7316.26万元，融资净买入-261.97万元。截至9月23日，中巨芯融资融券余额合计3.38亿元。 截至6月30日，中巨芯股东户数3.36万，较上期减少1.91%；人均流通股17215股，较上期增加1.95%。 2025年1月-6月，中巨芯实现营业收入5.67亿元，同比增长20.40%；归母净利润813.77万元，同比减少 64.57%。 分红方面，中巨芯A股上市后累计派现2215.91万元。 机构持仓方面，截止2025年6月30日，中巨芯十大流通股东中，嘉实上证科创板芯片ETF（588200）位 居第三大流通股东，持股1397.78万股，为新进股东。国联安中证全指半导体产品与设备ETF联接A （007300）位居第四大流通股东，持股625.94万股，为新进股东。南方中证1000ETF（512100）位居第 五大流通股东，持股544.26万股，相比上期增加211.61万股。博时上证科创板100ETF联接A（019857） 位居第七大流通股东，持股419.24万股，相比上期增加86.70万股 ...

Core Viewpoint - Zhongjuxin Technology Co., Ltd. experienced a 5.1% decline in stock price, closing at 9.12 CNY per share, with a total market capitalization of 13.473 billion CNY as of September 23 [1] Company Overview - Zhongjuxin was established on December 25, 2017, and went public on September 8, 2023. The company is based in Quzhou, Zhejiang Province, and specializes in the research, production, and sales of electronic wet chemicals, electronic specialty gases, and precursor materials [1] - The revenue composition of Zhongjuxin is as follows: electronic wet chemicals account for 76.63%, electronic specialty gases and precursors for 21.25%, and other sources for 2.12% [1] Shareholder Information - Among the top ten circulating shareholders of Zhongjuxin, Bosera Fund's Bosera SSE STAR 100 ETF Linked A (019857) increased its holdings by 867,000 shares in Q2, bringing its total to 4.1924 million shares, which represents 0.73% of the circulating shares [2] - As of the latest data, the fund has incurred an estimated floating loss of approximately 2.0543 million CNY [2] Fund Performance - The Bosera SSE STAR 100 ETF Linked A (019857) was established on December 1, 2023, with a current size of 383 million CNY. Year-to-date, it has achieved a return of 48.25%, ranking 598 out of 4220 in its category. Over the past year, the return is 104.32%, ranking 469 out of 3814, and since inception, the return is 33.48% [2]

8月26日晚，中巨芯发布2025年上半年报告称，上半年，公司实现营业总收入5.67亿元，同比增长20.4%；归属于上市公司股东 的净利润813.77万元，同比下降64.57%；扣除非经常性损益的净利润为96.92万元，同比下降92.24%。其中，第二季度实现归属 于上市公司股东的净利润环比扭亏为盈。 | | | | 早征: 兀 中: 人民巾 | | --- | --- | --- | --- | | 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上年 | | | (1-6月) | | 同期增减(%) | | 营业收入 | 566.566.646.39 | 470,569,562.96 | 20.40 | | 利润息额 | 5.478.923.39 | 27.547.167.54 | -80.11 | | 归属于上市公司股东的净利润 | 8.137.661.54 | 22.966.908.51 | -64.57 | | 归属于上市公司股东的扣除非经常性 损益的净利润 | 969 199 85 | 12.484.176.92 | -92.24 | | 经营活动产生的现金流量净额 | 77.122.969 ...

Investment Rating - The report maintains an "Accumulate" investment rating for the company [3][7]. Core Views - The company achieved a total revenue of 567 million yuan in the first half of 2025, representing a year-on-year increase of 20.40%. However, the net profit attributable to shareholders decreased by 64.57% year-on-year to 8.14 million yuan due to market conditions and increased competition [1][7]. - The electronic wet chemical segment generated revenue of 434.15 million yuan, up 25.57% year-on-year, while the electronic specialty gases and precursors segment saw revenue of 120.42 million yuan, a 10.49% increase year-on-year [7]. - The company is focusing on R&D, with R&D expenses amounting to 40.60 million yuan, which is 7.17% of total revenue, reflecting a 38.70% increase year-on-year [7]. - The company is expected to achieve revenues of 1.29 billion yuan, 1.62 billion yuan, and 1.95 billion yuan in 2025, 2026, and 2027 respectively, with year-on-year growth rates of 26%, 25%, and 20% [7][8]. Financial Data and Valuation - The company’s total revenue is projected to grow from 894 million yuan in 2023 to 1.95 billion yuan in 2027, with corresponding year-on-year growth rates of 12%, 15%, 26%, 25%, and 20% [2][10]. - The net profit attributable to shareholders is expected to increase from 14 million yuan in 2023 to 24 million yuan in 2027, with growth rates of 30%, -27%, 21%, 53%, and 31% respectively [8][11]. - The company’s PE ratios for 2025, 2026, and 2027 are projected to be 1100.2, 718.1, and 548.1 respectively, indicating a valuation above the industry average [7][11]. Stock Performance - The company's stock has shown a 14% absolute performance over the past month, a -1% performance over six months, and a 58% performance over the past year [5].

Core Viewpoint - The report highlights the financial performance and operational strategies of Grandit Co., Ltd. for the first half of 2025, indicating a significant increase in revenue but a decline in net profit due to market challenges and rising costs [1][9]. Financial Performance - The company achieved a total revenue of 566.57 million yuan, representing a year-on-year increase of 20.40% [4]. - The total profit decreased by 80.11% to 5.48 million yuan, while the net profit attributable to shareholders fell by 64.57% to 8.14 million yuan [4][9]. - The net cash flow from operating activities increased by 86.75% to 77.12 million yuan [4]. - Basic earnings per share dropped by 64.52% to 0.0055 yuan [4]. Industry Overview - The company operates in the electronic chemical materials sector, focusing on electronic wet chemicals, electronic specialty gases, and precursor materials, primarily used in integrated circuits, display panels, and photovoltaic manufacturing [6][9]. - The semiconductor materials sector is crucial for the semiconductor industry, influencing chip performance and technological advancements [6][9]. Business Operations - The company employs a sales-driven production model, focusing on customer demand to guide production planning [8]. - The main revenue comes from sales to downstream clients in integrated circuits, display panels, and photovoltaic sectors [9]. - The company has established a comprehensive R&D, procurement, production, quality control, and sales system, emphasizing innovation and product quality [9][10]. Research and Development - R&D expenses amounted to 40.60 million yuan, accounting for 7.17% of total revenue, reflecting a 38.70% increase year-on-year [9]. - The company has received 59 authorized invention patents, showcasing its commitment to technological innovation [12][13]. Market Strategy - The company aims to enhance operational efficiency and market strategies by benchmarking against industry leaders [10]. - It focuses on customer satisfaction by providing tailored product solutions and improving delivery capabilities [10][11]. Competitive Advantage - The company maintains a competitive edge through continuous technological innovation and a highly skilled R&D team [12][13]. - It has established long-term partnerships with major clients, ensuring stable demand and enhancing brand influence [15].

Group 1: Zhongjuxin - In 2024, Zhongjuxin's revenue will primarily come from the integrated circuit sector, accounting for nearly 74% of total revenue, with a slow recovery in semiconductor market demand [1] - The photovoltaic industry is experiencing negative gross margins, and the company will focus on integrated circuit clients in the future [1] - Electronic specialty gases generated revenue of 247 million yuan with a gross margin of 20.70%, mainly from high-purity chlorine [1] - The second phase of electronic specialty gases products will enhance gross margins, while the electronic wet chemical segment is facing declining margins due to industry competition [1] - The company reported a loss in Q4 due to increased labor costs, R&D investments, and year-end project expenses [1] - Overseas sales revenue is approximately 90 million yuan, with sales to the U.S. accounting for less than 1% of total revenue, indicating limited impact [1] - The company plans to expand market efforts and overseas sales channels in 2025 [1] Group 2: Jiuzhou Pharmaceutical - Jiuzhou Pharmaceutical indicated that the suspension of the PLI plan in India benefits raw material drug manufacturers in other countries, with domestic raw material prices stabilizing [2] - The CDMO business is expected to see a 15% year-on-year increase in new projects and a 20% increase in contract value in 2024, with revenue nearing 3.9 billion yuan and nearly 80% from overseas clients [2] - The company anticipates a recovery of CDMO gross margins to around 40% by 2025 [2] - In Q1, the overall capacity utilization rate was approximately 60%, with capital expenditures planned to be controlled at 500-600 million yuan in 2025 [2] - The company aims to introduce leading talents in the fields of peptides, DC, and small nucleic acids over the next three years [2] - Jiuzhou Pharmaceutical plans to provide services to over 70 clients in 2024, with nearly 30 new clients onboarded, focusing on inhalation formulations and liposome technology platforms [2]

股票简称：中巨芯 股票代码：688549 中巨芯科技股份有限公司 Grandit Co.,Ltd. 浙江省衢州市东南时代城 3 幢 857 室 首次公开发行股票 科创板上市公告书 保荐人（主承销商） 上海市黄浦区广东路 689 号 二〇二三年九月七日 中巨芯科技股份有限公司 上市公告书 特别提示 中巨芯科技股份有限公司（以下简称"中巨芯"、"发行人"、"公司"、 "本公司"）股票将于 2023 年 9 月 8 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 1 中巨芯科技股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不 表明对本公司的任何保证。 本 公 司 提 醒 广 大 投 资 者 认 真 阅 读 刊 载 于 上 海 证 券 交 易 所 网 站 （http://w ...

本次股票发行后拟在科创板市场上市，该市场具有较高的投资风险。科创板公司 具有研发投入大、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解科创板市场的投资风险及本公司所披露的风险 因素，审慎作出投资决定。 中巨芯科技股份有限公司 Grandit Co.,Ltd. （浙江省衢州市东南时代城 3 幢 857 室） 首次公开发行股票并在科创板上市 招股说明书 保荐人（主承销商） 上海市广东路 689 号 中巨芯科技股份有限公司 招股说明书 声明及承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 中巨芯科技股份有限公司 招股说明书 本次发行概况 | 发行股票类型 ...

本次股票发行后拟在科创板市场上市，该市场具有较高的投资风险。科创板公司 具有研发投入大、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解科创板市场的投资风险及本公司所披露的风险 因素，审慎作出投资决定。 中巨芯科技股份有限公司 Grandit Co.,Ltd. （浙江省衢州市东南时代城 3 幢 857 室） 首次公开发行股票并在科创板上市 招股意向书 上海市广东路 689 号 保荐人（主承销商） 中巨芯科技股份有限公司 招股意向书 声明及承诺 中巨芯科技股份有限公司 招股意向书 目录 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 中巨芯科技股份有限公司 招 ...

中巨芯科技股份有限公司 首次公开发行股票并在科创板上市招股意向书附录 | 序号 | 文件名称 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1 | | 2 | 法律意见书 | 34 | | 3 | 律师工作报告 | 450 | | 4 | 财务报告及审计报告 | 607 | | 5 | 发行人审计报告基准日至招股说明书签署日之间的相关财务报表 及审阅报告 | 748 | | 6 | 内部控制鉴证报告 | 773 | | 7 | 经注册会计师鉴证的非经常性损益明细表 | 787 | | 8 | 公司章程（草案） | 801 | | 9 | 关于同意中巨芯科技股份有限公司首次公开发行股票注册的批复 | 847 | 海通证券股份有限公司 关于中巨芯科技股份有限公司 首次公开发行股票并在科创板上市 之 发行保荐书 保荐人（主承销商） （上海市广东路 689 号） 二〇二三年六月 声 明 本保荐人及保荐代表人根据《中华人民共和国公司法》（下称"《公司法》"）、 《中华人民共和国证券法》（下称"《证券法》"）、《证券发行上市保荐业务管理 办法》（下称"《保荐管理办法》"）、《首次公开发 ...